%PDF-1.7
%
1 0 obj
<>>>
endobj
2 0 obj
<>stream
2019-12-16T11:07:45-05:00
2019-12-16T11:07:48-05:00
2019-12-16T11:07:48-05:00
Adobe InDesign CC 13.1 (Windows)
uuid:a0e10cc6-460b-4de3-b210-c377f47635ee
xmp.did:4A42F9656056E111960DCE8E95F0DF9D
xmp.id:4928f34e-182f-a542-a3ce-bf5750ae1f2b
proof:pdf
xmp.iid:81495003-1dd2-534b-898c-6dc6a69e3f69
xmp.did:340b6d8a-071b-d542-9d7f-5fbaaf7192f1
xmp.did:4A42F9656056E111960DCE8E95F0DF9D
default
converted
from application/x-indesign to application/pdf
Adobe InDesign CC 13.1 (Windows)
/
2019-12-16T11:07:45-05:00
application/pdf
Adobe PDF Library 15.0
False
endstream
endobj
12 0 obj
<>
endobj
3 0 obj
<>
endobj
5 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
6 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
8 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
9 0 obj
<>/Font<>/ProcSet[/PDF/Text]/Properties<>/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
10 0 obj
<>/Font<>/ProcSet[/PDF/Text]/Properties<>/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
11 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
14 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
51 0 obj
<>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
BT
/CS0 cs 1 scn
/GS0 gs
/T1_0 1 Tf
-0.01 Tc 8.5 0 0 8.5 171.2281 463.398 Tm
(1.)Tj
/Span<>> BDC
[( )-94.4 ( )]TJ
EMC
1.588 0 Td
[(Secondary stroke prevention with dual)-10 ( )]TJ
0 -1.2 Td
[(antiplatelet therapy carries a higher but)-10 ( )]TJ
0 -1.2 Td
[(acceptable risk of hemorrhagic complications.)-10 ( )]TJ
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
0 -1.2 Td
[(a. T)67 (rue)]TJ
0 -1.2 Td
(b. False)Tj
/CS0 cs 1 scn
/GS0 gs
/T1_0 1 Tf
-1.588 -2.894 Td
(2.)Tj
/Span<>> BDC
[( )-94.4 ( )]TJ
EMC
1.588 0 Td
[(Which is correct regarding the Ianiro et al)-9.9 ( )]TJ
0 -1.2 Td
[(study of the outcomes of treatment of a)-10 ( )]TJ
0.01 Tw 0 -1.2 Td
(recurrent )Tj
/T1_2 1 Tf
0 Tw 4.122 0 Td
(Clostridioides dif\037cile)Tj
/T1_0 1 Tf
( infection?)Tj
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
-4.122 -1.2 Td
[(a. Relative to antibiotic treatment, treatment)-10 ( )]TJ
0 -1.2 Td
[(with fecal microbiota transplant is associated)-10 ( )]TJ
0 -1.2 Td
[(with a higher incidence of bloodstream)-10 ( )]TJ
0.01 Tw 0 -1.2 Td
(infection.)Tj
0 Tw 0 -1.2 Td
[(b. Relative to antibiotic treatment, treatment)-10 ( )]TJ
0 -1.2 Td
[(with fecal microbiota transplant is associated)-10 ( )]TJ
0 -1.2 Td
[(with a shorter in-hospital length of stay)92 (.)]TJ
0 -1.2 Td
[(c. Relative to antibiotic treatment, treatment)-10 ( )]TJ
0 -1.2 Td
[(with fecal microbiota transplant is associated)-10 ( )]TJ
0 -1.2 Td
[(with increased mortality)91.9 (.)]TJ
0 -1.2 Td
[(d. Relative to antibiotic treatment, treatment)-10 ( )]TJ
0 -1.2 Td
[(with fecal microbiota transplant is associated)-10 ( )]TJ
0 -1.2 Td
[(with an increased risk of subsequent)-10 ( )]TJ
0 -1.2 Td
(recurrence of )Tj
/T1_3 1 Tf
(C. dif\037cile)Tj
/T1_1 1 Tf
( infection.)Tj
/CS0 cs 1 scn
/GS0 gs
/T1_0 1 Tf
21.308 26.894 Td
(3.)Tj
/Span<>> BDC
[( )-94.4 ( )]TJ
EMC
1.588 0 Td
[(What is one reason the CDC and ACIP)-10 ( )]TJ
0 -1.2 Td
[(updated their recommendations regarding the)-9.9 ( )]TJ
0 -1.2 Td
[(administration of the 13-valent pneumococcal)-10 ( )]TJ
0.01 Tw 0 -1.2 Td
(vaccine?)Tj
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
0 Tw 0 -1.2 Td
[(a. This vaccine is no longer considered)-10 ( )]TJ
0 -1.2 Td
(effective for anyone.)Tj
0 -1.2 Td
[(b. Herd immunity from pediatric vaccination)-10 ( )]TJ
0 -1.2 Td
(has been effective.)Tj
0 -1.2 Td
[(c. The manufacturer of the 13-valent vaccine is)-10 ( )]TJ
0 -1.2 Td
[(working on a new formulation, which means)-9.9 ( )]TJ
0 -1.2 Td
(more clinical trials will be needed.)Tj
0 -1.2 Td
[(d. The manufacturer announced it will cut)-10 ( )]TJ
0 -1.2 Td
(back production of the 13-valent vaccine.)Tj
/CS0 cs 1 scn
/GS0 gs
/T1_0 1 Tf
-1.588 -2.894 Td
(4.)Tj
/Span<>> BDC
[( )-94.4 ( )]TJ
EMC
1.588 0 Td
[(A vegetarian diet vs. a diet inclusive of red)-10 ( )]TJ
0 -1.2 Td
(meat increases risk for:)Tj
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
0 -1.2 Td
(a. ischemic stroke.)Tj
0 -1.2 Td
(b. acute myocardial infarction.)Tj
0 -1.2 Td
(c. ischemic heart disease.)Tj
0 -1.2 Td
(d. hemorrhagic stroke.)Tj
ET
0.86 0.57 0 0.16 K
0.325 w
/GS0 gs
q 1 0 0 1 221.9662 679.9689 cm
0 0 m
69.04 0 l
S
Q
BT
/GS1 gs
/TT0 1 Tf
0.01 Tc -0.01 Tw 9.25 0 0 9.25 163.2662 736.0122 Tm
(REFERENCES)Tj
/TT1 1 Tf
-0.025 Tc 0 Tw 0 -1.189 Td
(1.)Tj
/Span<>> BDC
( )Tj
EMC
1.946 0 Td
[(Shionogi Inc. FETROJA \(cefiderocol\) approved by)-24.9 ( )]TJ
0 -1.189 Td
[(the FD)17.6 (A for treatment of complicated urinary tract)-25.2 ( )]TJ
0 -1.189 Td
[(infections \(cUTI\) in adult patients with limited or)-25.1 ( )]TJ
0 -1.189 Td
[(no alternative treatment options, Nov)77.8 (. 14, 2019.)-24.9 ( )]TJ
0 -1.189 Td
(Available at: )Tj
0.86 0.57 0 0.16 k
/GS0 gs
0.025 Tw (http://bit.ly/343Qot1)Tj
0 0 0 1 k
/GS1 gs
0 Tw [(. Accessed Dec.)-25 ( )]TJ
0 -1.189 Td
(9, 2019.)Tj
-1.946 -1.189 Td
(2.)Tj
/Span<>> BDC
( )Tj
EMC
1.946 0 Td
[(Zhanel GG, Golden AR, Zelenitsky S, et al.)-25 ( )]TJ
0 -1.189 Td
[(Cefiderocol: A siderophore cephalosporin with)-24.8 ( )]TJ
0 -1.189 Td
(activity against carbapenem-resistant and multidrug-)Tj
0 -1.189 Td
(resistant Gram-negative )Tj
/TT2 1 Tf
0.025 Tw (Bacilli)Tj
/TT1 1 Tf
(. )Tj
/TT2 1 Tf
11.117 0 Td
(Drugs)Tj
/TT1 1 Tf
0 Tw ( 2019;79:)Tj
0 Tc 5.586 0 Td
( )Tj
-0.025 Tc 0.025 Tw -16.703 -1.189 Td
(271-289.)Tj
0 Tw -1.946 -1.189 Td
(3.)Tj
/Span<>> BDC
( )Tj
EMC
1.946 0 Td
[(Y)109.9 (amano Y)152 (. In vitro activity of cefiderocol against a)-25.1 ( )]TJ
0 -1.189 Td
[(broad range of clinically important Gram-negative)-25.1 ( )]TJ
0.025 Tw 0 -1.189 Td
(bacteria. )Tj
/TT2 1 Tf
0 Tw 3.226 0 Td
(Clin Infect Dis)Tj
/TT1 1 Tf
( 2019;69\(Suppl 7\):)Tj
0 Tc 11.49 0 Td
( )Tj
-0.025 Tc 0.025 Tw -14.715 -1.189 Td
(S544-S551.)Tj
0 Tw -1.946 -1.189 Td
(4.)Tj
/Span<>> BDC
( )Tj
EMC
1.946 0 Td
[(ClinicalT)155.7 (rials.gov)77.8 (. Study of S-649266 or best avail)]TJ
0 Tc (-)Tj
-0.025 Tc 0 -1.189 Td
[(able therapy for the treatment of severe infections)-25.2 ( )]TJ
0 -1.189 Td
[(caused by carbapenem-resistant Gram-negative)-25 ( )]TJ
0 -1.189 Td
[(pathogens \(CREDIBLE - CR\). Available at:)-24.9 ( )]TJ
0 Tc 15.227 0 Td
( )Tj
ET
/GS0 gs
q 1 0 0 1 384.2537 734.9689 cm
0 0 m
66.904 0 l
S
Q
q 1 0 0 1 424.9537 624.9689 cm
0 0 m
66.343 0 l
S
Q
q 1 0 0 1 394.2454 536.9689 cm
0 0 m
68.34 0 l
S
Q
BT
0.86 0.57 0 0.16 k
-0.025 Tc 0.025 Tw 9.25 0 0 9.25 384.2537 736.0122 Tm
(http://bit.ly/350r1cZ)Tj
0 0 0 1 k
/GS1 gs
0 Tw (. Accessed Dec. 9, 2019.)Tj
-1.946 -1.189 Td
(5.)Tj
/Span<>> BDC
( )Tj
EMC
1.946 0 Td
[(P)54.7 (ortsmouth S, van V)54.8 (eenhuyzen D, Echols R, et)-25.1 ( )]TJ
0 -1.189 Td
[(al. Cefiderocol versus imipenem-cilastatin for the)-25.1 ( )]TJ
0 -1.189 Td
[(treatment of complicated urinary tract infections)-25.2 ( )]TJ
0 -1.189 Td
[(caused by Gram-negative uropathogens: A phase)-25 ( )]TJ
0 -1.189 Td
[(2, randomised, double-blind, non-inferiority trial.)-25 ( )]TJ
/TT2 1 Tf
0 -1.189 Td
[(L)17.6 (ancet Infect Dis)]TJ
/TT1 1 Tf
( 2018;18:1319-1328.)Tj
-1.946 -1.189 Td
(6.)Tj
/Span<>> BDC
( )Tj
EMC
1.946 0 Td
[(W)54.9 (orld Health Organization. Global priority list)-25.2 ( )]TJ
0 -1.189 Td
[(of antibiotic-resistant bacteria to guide research,)-25 ( )]TJ
0 -1.189 Td
[(discovery)87 (, and development of new antibiotics.)-24.9 ( )]TJ
0 -1.189 Td
(Available at: )Tj
0.86 0.57 0 0.16 k
/GS0 gs
0.025 Tw (http://bit.ly/36hTbAj)Tj
0 0 0 1 k
/GS1 gs
0 Tw [(. Accessed)-25.2 ( )]TJ
0 Tc 15.566 0 Td
( )Tj
-0.025 Tc -15.566 -1.189 Td
(Dec. 9, 2019.)Tj
-1.946 -1.189 Td
(7.)Tj
/Span<>> BDC
( )Tj
EMC
1.946 0 Td
[(Doi Y)151.9 (. T)155.7 (reatment options for carbapenem-resistant)-25.1 ( )]TJ
0 -1.189 Td
(Gram-negative bacterial infections. )Tj
/TT2 1 Tf
(Clin Infect Dis)Tj
/TT1 1 Tf
0 Tc 17.245 0 Td
( )Tj
-0.025 Tc 0.025 Tw -17.245 -1.189 Td
(2019;69:S565-S575.)Tj
0 Tw -1.946 -1.189 Td
(8.)Tj
/Span<>> BDC
( )Tj
EMC
1.946 0 Td
[(ClinicalT)155.7 (rials.gov)77.8 (. Clinical study of S-649266 for the)-25 ( )]TJ
0 -1.189 Td
[(treatment of nosocomial pneumonia caused by)-24.9 ( )]TJ
0 -1.189 Td
[(Gram-negative pathogens \(APEKS-NP\). Available)-25.1 ( )]TJ
0.025 Tw 0 -1.189 Td
(at: )Tj
0.86 0.57 0 0.16 k
/GS0 gs
1.08 0 Td
[(http://bit.ly/2RKL)17.4 (aAb)]TJ
0 0 0 1 k
/GS1 gs
0 Tw (. Accessed Dec. 9, 2019.)Tj
ET
endstream
endobj
52 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Subtype/Form>>stream
/CS0 cs 0.07 scn
/GS0 gs
18 103.68 120.33 652.32 re
f
18 36 539.325 53.473 re
f
BT
0 0 0 1 k
/GS1 gs
/TT0 1 Tf
0 Tc 0 Tw 0 Ts 100 Tz 0 Tr 7 0 0 7 27.8983 78.3659 Tm
(Interested in reprints or posting an article to your )Tj
0 -1.143 Td
[(company)-55.8 (\222s site? There are numerous opportunities for )]TJ
0 -1.143 Td
(you to leverage editorial recognition for the benefit of )Tj
0 -1.143 Td
(your brand. Call us at \(800\) 688-2421 or email us at )Tj
0 -1.143 Td
(reprints@reliasmedia.com.)Tj
25.217 4.571 Td
(Discounts are available for group subscriptions, multiple )Tj
0 -1.143 Td
(copies, site licenses, or electronic distribution. For pricing )Tj
0 -1.143 Td
(information, please contact our Group Account Managers )Tj
0 -1.143 Td
(at groups@reliasmedia.com or \(866\) 213-0844.)Tj
19.248 0 Td
( )Tj
5.969 3.429 Td
[(T)175 (o reproduce any part of R)17.6 (elias Media newsletters for )]TJ
0 -1.143 Td
(educational purposes, please contact The Copyright )Tj
0 -1.143 Td
(Clearance Center for permission at info@copyright.com )Tj
0 -1.143 Td
(or \(978\) 750-8400.)Tj
ET
/CS0 CS 1 SCN
3 w 4 M 0 j 0 J
/GS0 gs
q 1 0 0 1 138.6633 754.5 cm
0 0 m
437.337 0 l
S
Q
/CS0 cs 1 scn
163.925 169.24 391.566 16.256 re
f
BT
0 scn
0.041 Tc -0.016 Tw 10 0 0 10 319.3918 174.6651 Tm
[(CM)1 (E)16 ( O)4.1 (B)11.9 (J)2.4 (E)24.3 (C)-1.4 (T)14.1 (I)0.5 (VE)9.9 (S)]TJ
ET
1 scn
163.328 479.513 392.414 18.174 re
f
0.25 w
163.391 219.925 392.225 259.463 re
S
BT
0 scn
0.037 Tc -0.012 Tw 10 0 0 10 318.7734 485.7422 Tm
[(C)-3.7 (M)-3 (E)12 ( Q)1.9 (U)-3.3 (E)5.9 (S)4.8 (T)10.1 (ION)-11.3 (S)]TJ
1 scn
0.01 Tc 0 Tw 9 0 0 9 163.9585 159.8295 Tm
[(Upon completion of this educational activity)87.1 (, participants should be able to:)]TJ
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
0 Tc 6 0 0 6 25.2 744.168 Tm
(PHYSICIAN EDITOR)Tj
/TT0 1 Tf
0 -1.167 Td
(Stephen A. Brunton, MD)Tj
/TT1 1 Tf
-0.025 Tc 0 -1.167 Td
[(Adjunct P)35.6 (rofessor of Pharmacy P)35.7 (ractice)]TJ
0 -1.167 Td
(College of Pharmacy)Tj
0 Tc 7.469 0 Td
( )Tj
-0.025 Tc -7.469 -1.167 Td
[(R)17.5 (oseman University of Health Sciences)]TJ
0 Tc 13.998 0 Td
( )Tj
-0.025 Tc -13.998 -1.167 Td
[(Salt L)17.4 (ake City)]TJ
/T1_0 1 Tf
0 Tc 0 -2.667 Td
(PEER REVIEWER)Tj
/TT0 1 Tf
0 -1.167 Td
[(Gerald R)17.7 (oberts, MD)]TJ
/TT1 1 Tf
0 -1.167 Td
(Senior Attending Physician )Tj
( )Tj
0 -1.167 Td
[(L)17.4 (ong Island Jewish Medical Center)]TJ
13.107 0 Td
( )Tj
-13.107 -1.167 Td
(NS/LIJ Health Care System)Tj
10.378 0 Td
( )Tj
-10.378 -1.167 Td
[(New Hyde P)54.8 (ark, NY)]TJ
/T1_0 1 Tf
0 -2.333 Td
[(EDITORIAL ADVISOR)92.1 (Y BOARD)]TJ
/TT0 1 Tf
0 -1.167 Td
(James Chan, PharmD, PhD)Tj
/TT1 1 Tf
0 -1.167 Td
[(Associate Clinical P)34.4 (rofessor)]TJ
( )Tj
0 -1.167 Td
(School of Pharmacy)Tj
7.563 0 Td
( )Tj
-7.563 -1.167 Td
[(University of California, San F)54 (rancisco)]TJ
/TT0 1 Tf
0 -1.917 Td
[(William T)156.1 (. Elliott, MD, F)36.2 (A)17.5 (CP)]TJ
/TT1 1 Tf
0 -1.167 Td
[(Assistant Clinical P)33.9 (rofessor of Medicine )]TJ
0 -1.167 Td
[(University of California, San F)54 (rancisco)]TJ
/TT0 1 Tf
0 -2.333 Td
(David Fiore, MD)Tj
/TT1 1 Tf
0 -1.167 Td
[(P)35.7 (rofessor of F)35.9 (amily Medicine)]TJ
0 -1.167 Td
[(University of Nevada, R)17.1 (eno)]TJ
/TT0 1 Tf
0 -1.917 Td
[(K)17.7 (en Grauer)100.9 (, MD)]TJ
/TT1 1 Tf
0 -1.167 Td
[(P)35.7 (rofessor Emeritus in F)35.1 (amily )]TJ
( )Tj
0 -1.167 Td
(Medicine, College of Medicine,)Tj
0 -1.167 Td
(University of Florida)Tj
/TT0 1 Tf
0 -2.333 Td
(Seema Gupta, MD, MSPH)Tj
/TT1 1 Tf
0 -1.167 Td
[(Clinical Assistant P)33.9 (rofessor)100.4 (,)]TJ
0 -1.167 Td
[(Department of F)35.5 (amily and Community)]TJ
0 -1.167 Td
(Health, Joan C. Edwards School of Medicine)Tj
0 -1.167 Td
(Marshall University)Tj
0 -1.167 Td
(Huntington, WV)Tj
/TT0 1 Tf
-0.01 Tc 0 -1.917 Td
[(Harold L. K)17.8 (arpman, MD, F)35.8 (A)17.5 (CC, F)35.7 (A)17.6 (CP)]TJ
/TT1 1 Tf
-0.03 Tc 0 -1.167 Td
[(Clinical P)35.7 (rofessor of Medicine)]TJ
0 Tc 10.349 0 Td
( )Tj
-0.03 Tc -10.349 -1.167 Td
(David Geffen School of Medicine at UCLA)Tj
/TT0 1 Tf
0 Tc 0 -1.917 Td
[(Louis K)17.8 (uritzky)87.5 (, MD)]TJ
/TT1 1 Tf
0 -1.167 Td
[(Clinical Assistant P)33.9 (rofessor)100.4 (, )]TJ
0 -1.167 Td
(University of Florida, Gainesville)Tj
/TT0 1 Tf
0 -1.917 Td
[(Martin S. Lipsky)87.5 (, MD)]TJ
/TT1 1 Tf
-0.03 Tc 0 -1.167 Td
[(Chancellor)100.5 (, South Jordan Campus, R)17.5 (oseman)-29.9 ( )]TJ
0 -1.167 Td
(University of Health Sciences, South Jordan, UT)Tj
/TT0 1 Tf
0 Tc 0 -1.917 Td
[(Joseph E. Scherger)101.6 (, MD, MPH)]TJ
/TT1 1 Tf
0 -1.167 Td
[(Core F)35.8 (aculty)86.9 (,)]TJ
0 -1.167 Td
[(Eisenhower Health F)35.5 (amily Medicine R)16.7 (esidency )]TJ
0 -1.167 Td
[(P)35.7 (rogram,)]TJ
0 -1.167 Td
[(Eisenhower Health Center)99.9 (, L)17.5 (a Quinta, CA)-18.8 (;)]TJ
0 -1.167 Td
[(Clinical P)34.8 (rofessor)100.4 (,)]TJ
0 -1.167 Td
[(K)17.6 (eck School of Medicine,)]TJ
0 -1.167 Td
[(University of Southern California, L)16.8 (os Angeles)]TJ
/TT0 1 Tf
0 -1.917 Td
(Allan J. Wilke, MD, MA)Tj
/TT1 1 Tf
0 -1.167 Td
[(P)35.7 (rofessor and Chair)]TJ
7.542 0 Td
( )Tj
-7.542 -1.167 Td
[(Department of F)35.5 (amily Medicine)]TJ
12.045 0 Td
( )Tj
-12.045 -1.167 Td
[(W)54.9 (estern Michigan University)]TJ
10.92 0 Td
( )Tj
-10.92 -1.167 Td
[(School of Medicine, K)17.8 (alamazoo)]TJ
/T1_0 1 Tf
-0.01 Tc 0.01 Tw 0 -2.5 Td
(EDITOR)Tj
/TT0 1 Tf
0 Tw 0 -1.25 Td
(Jonathan Springston)Tj
/T1_0 1 Tf
0.01 Tw 0 -2.5 Td
(EDITOR)Tj
/TT0 1 Tf
0 Tw 0 -1.25 Td
(Jason Schneider)Tj
/T1_0 1 Tf
0 -2.5 Td
(EDITORIAL GROUP MANAGER)Tj
/TT0 1 Tf
0 -1.333 Td
(Leslie Coplin)Tj
/T1_0 1 Tf
0 -2.667 Td
[(ACCREDIT)74 (A)74 (TIONS MANAGER)]TJ
/TT0 1 Tf
0 -1.25 Td
(Amy M. Johnson, MSN, RN, CPN)Tj
/CS0 cs 1 scn
/GS0 gs
/TT1 1 Tf
0.01 Tc 9 0 0 9 162.7662 146.945 Tm
(\225)Tj
/Span<>> BDC
( )Tj
EMC
1.111 0 Td
(describe new findings in the differential diagnosis and treatment of var\
ious diseases;)Tj
-1.111 -1.222 Td
(\225)Tj
/Span<>> BDC
( )Tj
EMC
1.111 0 Td
[(describe the advantages, disadvantages, and controversies surrounding th\
e latest advances in the diagnosis)9.8 ( )]TJ
/Span<>> BDC
-1.111 -1.222 Td
[( )-238 ( )]TJ
EMC
1.111 0 Td
(and treatment of disease;)Tj
-1.111 -1.222 Td
(\225)Tj
/Span<>> BDC
( )Tj
EMC
1.111 0 Td
(identify cost-effective treatment regimens;)Tj
-1.111 -1.222 Td
(\225)Tj
/Span<>> BDC
( )Tj
EMC
1.111 0 Td
(explain the advantages and disadvantages of new disease screening proced\
ures.)Tj
ET
endstream
endobj
53 0 obj
<>
endobj
54 0 obj
<>
endobj
55 0 obj
<>
endobj
60 0 obj
<>
endobj
61 0 obj
<>stream
HdNV{q)>J\> i\?m 6eȷ<O/fst]~x{_Nϯ7ww˛oxx2r/?2އp?D??yz{qfzOt:m-_7͆"uDsF'OuOD'&2G'j~"7vG?j$O ?O'I?ɟ'$O ?O'I?ɟ'3,Ɵ?gYyV2ee*)U,S,XXVLbbY2Ų++*V(VTPXXQBbbE
ŊnL_//?R_/WU_W+*_WU_W+*_o7M7&o
o7M7&o
:zX.oز>*+zR9OS Mb
endstream
endobj
62 0 obj
<>stream
HtV TSW[#BHآ,E@+HX)EX\`@bZE:*Qk1:ZX֊(.3b?9}=0 ^X i67gD&蜢,k] g*/+ ak~ ͟>T$e6$&.{|)TSHErςH>G9Ugd)<]̼
pEYVy*+~ mqVQ"7^
e`~;0e̳\ <+[J5 pٱrH,
dIE_raY)}I~j:vG"ITʻ}GF^%Yţ[t#TzGRȨSl\JW_M:#Fƌ7 Lh4͌)YͳN6xdfiYsު|{.Zd;U˖XV^n>aG>-[};vtg{lٻo
_:|ˣǾ:x듧9}^bW^~w@R@h! d2SPÒ8*<;wGZvVK>T}^G!0y^acYΥدX_Mprzowl&tR%NՙABo w7]zw.S?v{ٹ2LzdF-`)c~;x+1vbV:c8n?،]txm$ꑍA. pф8xj\F3. ¿SQi(tcfVD)QY[J8OY!R~ADWтt]\žN|FZsuBUSlv[:I}-Vwr>Q*N`=X* c {DOl,``P#c,;Q(PG^c+$,fB< Le0O*>C"ehXB
3&L&jV@qi(SQwX(T\ºKf'еKlFDždQrV-p){wd"Kr<ȔF!ZV~]bAq
GfΎl9BE"d:8rb C:GΦ ]K'jqˍ S a!0igwj>2 "l*e#ϥU)ħLڵ'hGwT RL3Ntx&ɒ(CVeڒƤkOMEEFԪd
i69NgZ$N6>La-gl=ҙuhf
ƥHM)Qt^[XGg$cs\!'vZөu|P{c_L7e9F;|ٕ%$bA
%$P&/b[f/eҳg]\k:(EV _Ag(MM